Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of <i>KRAS</i> -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study
Most Cited Paper
in Microtubule and mitosis dynamics
18 Months Post-Publication
Class of 2026
“Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of <i>KRAS</i> -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
onvansertib · PLK1 · KRAS-mutant colorectal cancer · FOLFIRI · bevacizumab · second-line treatment · metastatic colorectal cancer · phase Ib clinical trial · irinotecan · circulating tumor DNA (ctDNA) · KRAS wild-type isogenic cells · xenograft model · neutropenia · recommended phase II dose · partial response · ctDNA dynamics · oxaliplatin exposure · antitumor activity
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Microtubule and mitosis dynamics Papers, Class of 2026. https://pri.pepkio.com/top-papers/microtubule-and-mitosis-dynamics/2026. Accessed 2026-07-23. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459